EGFR and heart failure: One patient in the MINO group and 12 patients in the control group discontinued first-line EGFR-TKIs due to adverse events (hepatic dysfunction, N = 7; skin rash, N = 2; lung injury, N = 2; gastrointestinal toxicity, N = 1; heart failure, N = 1).